Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP.
Motapizone (10 μM; 15 min before oxidants) results 20% inhibition rate for cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages with oxidative stress conditions, but the inhibitory effect is not affected by oxidative stress[1].
References:
[1]. Milara J, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011 Apr;41(4):535-46.
[2]. Borbe HO, et al. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 1986;20:249-57.